BidaskClub cut shares of LivaNova (NASDAQ:LIVN) from a buy rating to a hold rating in a research report released on Saturday morning.
LIVN has been the subject of several other reports. Needham & Company LLC lifted their target price on shares of LivaNova to $93.00 and gave the stock a buy rating in a research note on Tuesday, November 21st. Canaccord Genuity reaffirmed a hold rating and issued a $76.00 target price on shares of LivaNova in a research note on Tuesday, November 14th. Zacks Investment Research cut shares of LivaNova from a buy rating to a hold rating in a research note on Thursday, December 21st. Finally, ValuEngine raised shares of LivaNova from a hold rating to a buy rating in a research note on Friday, February 2nd. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating and five have issued a buy rating to the company’s stock. LivaNova presently has a consensus rating of Hold and an average target price of $81.43.
Shares of LivaNova (LIVN) traded down $0.78 during trading on Friday, hitting $87.55. The company had a trading volume of 544,529 shares, compared to its average volume of 386,677. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.14 and a quick ratio of 1.79. LivaNova has a 1 year low of $48.16 and a 1 year high of $92.31. The firm has a market cap of $4,228.31, a P/E ratio of -162.13, a P/E/G ratio of 2.74 and a beta of 0.75.
In other LivaNova news, Director Daniel Jeffrey Moore sold 1,000 shares of LivaNova stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $83.32, for a total value of $83,320.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders sold a total of 3,000 shares of company stock valued at $246,270 over the last ninety days. 0.28% of the stock is owned by corporate insiders.
Hedge funds and other institutional investors have recently made changes to their positions in the company. Cerebellum GP LLC purchased a new stake in shares of LivaNova during the 4th quarter valued at $128,000. QS Investors LLC grew its stake in shares of LivaNova by 27,255.6% during the 4th quarter. QS Investors LLC now owns 2,462 shares of the company’s stock valued at $197,000 after buying an additional 2,453 shares during the period. Pillar Pacific Capital Management LLC purchased a new stake in shares of LivaNova during the 4th quarter valued at $208,000. Shelton Capital Management purchased a new stake in shares of LivaNova during the 3rd quarter valued at $209,000. Finally, Affinity Investment Advisors LLC purchased a new stake in shares of LivaNova during the 4th quarter valued at $211,000. 84.68% of the stock is owned by institutional investors.
COPYRIGHT VIOLATION NOTICE: “BidaskClub Downgrades LivaNova (LIVN) to Hold” was originally published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this story on another publication, it was illegally copied and republished in violation of US & international trademark & copyright law. The original version of this story can be read at https://sportsperspectives.com/2018/03/11/bidaskclub-downgrades-livanova-livn-to-hold.html.
LivaNova Company Profile
LivaNova PLC is a medical device company focused on the development and delivery of therapeutic solutions. The Company’s segments include Cardiac Surgery, Cardiac Rhythm Management, Neuromodulation and Other. The Cardiac Surgery segment is engaged in the development, production and sale of cardiovascular surgery products.
Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.